Taj Pharma Bags USFDA Nod For Colistimethate sodium injection
Indian pharmaceuticals group announced USFDA approval for Colistimethate sodium for injection and inhalation for United States market.
- (1888PressRelease) February 11, 2012 - Taj Pharma Group declared that it has bagged nod from USFDA to sell Colistimethate sodium for injection and inhalation in the United States. Each Injection contains Colistin 1 MIU - 1 Million International Units (1 MIU) Colistimethate Sodium.
In an interview with CNBC, Group CEO A.K.Singh said, 'the proposed U.S. launch will be very affordable for US citizens facing specific lung infections, the generics Colistimethate will be available at very reasonable prices benefitting the American hospitals'.
The company will sell Colistin 1 MIU is available in vial of 10 ml in Powder for solution for injection, infusion and inhalation.
Colistimethate sodium powder for inhalation (Colobreathe) for Pseudomonas aeruginosa lung infection in cystic fibrosis.
Inhalation may induce coughing or bronchospasm. Sore throat or mouth has been reported and may be due to Candida albicans infection or hypersensitivity. Skin rash may also indicate hypersensitivity; if this occurs, treatment should be withdrawn.
Colistin is contraindicated in patients with known hypersensitivity to colistimethate sodium (colistin) or to polymyxin B and in patients with myasthenia gravis.
Colistimethate sodium is a cyclic polypeptide antibiotic derived from Bacillus polymyxa var. colistinus and belongs to the polymyxin group. The polymyxin antibiotics are cationic surface-active agents that work by damaging the cell membrane. The resulting physiological effects are lethal to the bacterium. Polymyxins are selective for Gramnegative bacteria that have a hydrophobic outer membrane.
Taj Pharma Group declared that it has bagged nod from USFDA to sell Colistimethate sodium for injection and inhalation in the United States. Each Injection contains Colistin 1 MIU - 1 Million International Units (1 MIU) Colistimethate Sodium.
In an interview with CNBC, Group CEO A.K.Singh said, 'the proposed U.S. launch will be very affordable for US citizens facing specific lung infections, the generics Colistimethate will be available at very reasonable prices benefitting the American hospitals'.
The company will sell Colistin 1 MIU is available in vial of 10 ml in Powder for solution for injection, infusion and inhalation.
Colistimethate sodium powder for inhalation (Colobreathe) for Pseudomonas aeruginosa lung infection in cystic fibrosis.
Inhalation may induce coughing or bronchospasm. Sore throat or mouth has been reported and may be due to Candida albicans infection or hypersensitivity. Skin rash may also indicate hypersensitivity; if this occurs, treatment should be withdrawn.
Colistin is contraindicated in patients with known hypersensitivity to colistimethate sodium (colistin) or to polymyxin B and in patients with myasthenia gravis.
Colistimethate sodium is a cyclic polypeptide antibiotic derived from Bacillus polymyxa var. colistinus and belongs to the polymyxin group. The polymyxin antibiotics are cationic surface-active agents that work by damaging the cell membrane. The resulting physiological effects are lethal to the bacterium. Polymyxins are selective for Gramnegative bacteria that have a hydrophobic outer membrane.
About Taj Pharma India
Taj Pharmaceuticals Limited is known as a pharmaceuticals manufacturing company found and based in India. The company manufacturer's pharmaceuticals formulations and API for India and other countries. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Iran, Iraq and Asia Pacific. In recent EU-Indonesia Business Dialogue (EIBD) conference Taj Pharma Group was listed amongst top 10 pharmaceutical companies in EU by 2008 sales. The Group sales 16,234 ($M) making the company 12 ranked in EU by 2008 sales. Founded as a company for finished formulation marketing and Export and then entered Api and Agro business in 2004 and 2007 respectively.
About Network18
Network18 Media & Investments Limited (BSE: 532798, NSE: Network18) is an Indian media conglomerate with interests in television, print, internet, film, mobile content and allied businesses. Network 18 FinCap is the holding company for several media entities in India such as Television Eighteen India Ltd (TV18), IBN 18 Broadcast Ltd, Web 18, Studio 18,Shop 18,Infomedia 18 and Viacom 18. Raghav Bahl holds 51% shares of Network 18 Group. The group includes Network18, TV18, ibn18 and Infomedia18, all of which are listed in India on NSE & BSE. The company is owned by Raghav Bahl who has 51% stake in Network 18.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam